Nanologica AB

Research Nanologica AB (NICA) on Bullrun: valuation model: 135.7% undervalued, market cap SEK 167.67M, P/E 2.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerNICA
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Valuation signal135.7% undervalued
• Market capSEK 167.67M
• P/E2.0
• Financial periodFY2024
• RevenueSEK 14.54M
• Revenue growth907.5%
• Net income-SEK 65.63M
• Free cash flow-SEK 81.00M

Valuation Snapshot

Bullrun's latest valuation model marks Nanologica AB as 135.7% undervalued; latest market cap is SEK 167.67M; P/E is 2.0.

About Nanologica AB

Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 analogues and other peptides;

Frequently asked questions

Is Nanologica AB overvalued or undervalued?

Bullrun's valuation model currently marks Nanologica AB as 135.7% undervalued.

What is Nanologica AB's market cap?

Nanologica AB's market capitalization is SEK 167.67M.

What is Nanologica AB's P/E ratio?

Nanologica AB's price-to-earnings (P/E) ratio is 2.0.

What does Nanologica AB do?

Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally.